Accusure Insulin Syringe Recall: Needle May Detach from the Syringe

Two lots of Accusure insulin syringes have been recalled due to defective needles that can detach from the syringes during use, according to a notice posted by the FDA on Friday.

The Accusure insulin syringe recall was issued after the manufacturer, Qualtest Pharmaceuticals, Inc., received at least three reports of needles on the short needle syringes breaking off. If the needle detaches, it can slide back into the syringe during use, remain in the skin after injection or become stuck in the insulin vial.

The recall includes Accusure Insulin Syringes (1/2 cc – 31 G – Short Needle) with lot number 7CPT1 (Expiration 03/2012) – NDC 0603-7002-21. These needles were distributed between May 2007 and June 2008. The recall also includes Accusure Insulin Syringes (1/2 cc – 31 G – Short Needle) with lot number 6JCB1 (Expiration 10/2011) – NDC 0603-7001-21. The lot numbers can be found on the white paper backing on each syringe.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

Anyone with syringes affected by the insulin syringe recall has been urged by the manufacturer to stop using them and to contact Qualitest at 1-800-444-4011 for replacements. However, product liability lawyers recommend that any consumers who have suffered a severe physical injury requiring medical treatment as a result of the defective insulin syringes, should preserve any remaining syringes in a manner to prevent further use until it has been determined whether an insulin syring recall lawsuit will be pursued.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria
Port Catheter Infection Lawsuits Over Bard PowerPort Devices Claim Faulty Design Promotes Colonization of Bacteria (Posted today)

Hundreds of currently pending Bard PowerPort lawsuits over infections, fractures and migration injuries were consolidated into a multidistrict litigation (MDL), but now even more claims present similar allegations that the implantable port catheter system has dangerous design defects that were not adequately disclosed by the manufacturer.

Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters
Johnson & Johnson Increases Talcum Powder Settlement Offer by $1.1B: Reuters (Posted today)

A recent report suggests that Johnson & Johnson is offering an additional $1.1 billion to settle talcum powder lawsuits, as part of a proposed $9 billion deal that would resolve all ovarian cancer claims as part of a third bankruptcy filing by the manufacturer.

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted 3 days ago)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.